This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this study is to test the hypothesis that the optimal insulin secretagogue (antidiabetic drug) to normalize the postprandial insulin and glucose concentration will be one in which a low, constant concentration of drug is present at all times during the postprandial period. This low but steady concentration will normalize both early and late phase insulin secretion as well as controlling postprandial glucose concentration without enhancing the risk of late period hyperglycemia or hypoglycemia.
Showing the most recent 10 out of 568 publications